USA
GlobalBiotech & Genomic Medicine▲
Alzheimer's Disease Market Projected to Reach USD 4 Billion in 2025 with 22.7% CAGR Through 2036
The Alzheimer's disease market across the seven major markets was valued at approximately USD 4 billion in 2025 and is projected to expand at a CAGR of 22.7% through 2036, according to DelveInsight. The growth is driven by increasing disease prevalence, broader adoption of disease-modifying therapies, advancements in biomarker-based diagnosis, and a robust late-stage pipeline. Key emerging therapies include Masupirdine from Suven Life Sciences, Roche's Trontinemab, Annovis Bio's Buntanetap, AB Science's Masitinib, Eli Lilly's Remternetug, Axsome Therapeutics' AUVELITY, Biovie's Bezisterim, ALZHEON's Valiltramiprosate, TauRx Therapeutics' Hydromethylthionine mesylate, Bristol Myers Squibb's COBENFY, AriBio's AR1001, Acadia Pharmaceuticals' Remlifanserin, and Cerecin's Tricaprilin. The report highlights six late-stage candidates poised to enter the market, including Masupirdine, Trontinemab, AXS-05, COBENFY, Remternetug, and Buntanetap, each with distinct mechanisms of action and anticipated clinical milestones.
About megatrends
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Demand
LLY · Demand · Positive Eli Lilly's Remternetug is listed as a key emerging therapy in a growing Alzheimer's market.
ROP.SW · Demand · Positive Roche's Trontinemab is highlighted as a late-stage candidate in an expanding market.
AB.PA · Demand · Positive AB Science's Masitinib is mentioned as a key emerging therapy in the Alzheimer's market.
Alzheon, Inc. · Demand · Positive Alzheon's Valiltramiprosate is listed among key emerging therapies in the growing market.
Suven Life Sciences Ltd · Demand · Positive Suven Life Sciences' Masupirdine is a late-stage candidate in the expanding Alzheimer's market.
ANVS · Technology · Positive Buntanetap is highlighted as a late-stage candidate with anticipated clinical milestones.